Original Data

Rev Diabet Stud, 2017, 14(1):10-21 DOI 10.1900/RDS.2017.14.10

Benefits of Islet Transplantation as an Alternative to Pancreas Transplantation: Retrospective Study of More Than 10 Ten Years of Experience in a Single Center

Barbora Voglová1, Martina Zahradnická1, Peter Girman1, Jan Kríž1, Zuzana Berková1, Tomáš Koblas1, Ema Vávrová1, Lenka Németová1, Lucie Kosinová1, David Habart1, Eva Fábryová1, Eva Dovolilová1, Ivan Leontovyc1, Tomáš Neškudla1, Jan Peregrin2, Jozef Kovác2, Kvetoslav Lipár3, Matej Kocík3, Tomáš Marada3, Jirí Svoboda1, František Saudek1

1Department of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
2Department of Diagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
3Department of Transplant Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
Address correspondence to: Frantisek Saudek, e-mail: Frantisek.saudek@ikem.cz

Manuscript submitted June 6, 2017; accepted June 10, 2017.

Keywords: type 1 diabetes, hypoglycemia unawareness syndrome, islet transplantation, pancreas transplantation


BACKGROUND: Pancreas transplantation (PTx) represents the method of choice in type 1 diabetic patients with conservatively intractable hypoglycemia unawareness syndrome. In 2005, the Institute for Clinical and Experimental Medicine (IKEM) launched a program to investigate the safety potential of islet transplantation (ITx) in comparison to PTx. AIM: This study aims to compare the results of PTx and ITx regarding severe hypoglycemia elimination, metabolic control, and complication rate. METHODS: We analyzed the results of 30 patients undergoing ITx and 49 patients treated with PTx. All patients were C-peptide-negative and suffered from hypoglycemia unawareness syndrome. Patients in the ITx group received a mean number of 12,349 (6,387-15,331) IEQ/kg/person administered percutaneously into the portal vein under local anesthesia and radiological control. The islet number was reached by 1-3 applications, as needed. In both groups, we evaluated glycated hemoglobin, insulin dose, fasting and stimulated C-peptide, frequency of severe hypoglycemia, and complications. We used the Mann Whitney test, Wilcoxon signed-rank test, and paired t-test for analysis. We also individually assessed the ITx outcomes for each patient according to recently suggested criteria established at the EPITA meeting in Igls. RESULTS: Most of the recipients showed a significant improvement in metabolic control one and two years after ITx, with a significant decrease in HbA1c, significant elevation of fasting and stimulated C-peptide, and a markedly significant reduction in insulin dose and the frequency of severe hypoglycemia. Seventeen percent of ITx recipients were temporarily insulin-independent. The results in the PTx group were comparable to those in the ITx group, with 73% graft survival and insulin independence in year 1, 68% 2 years and 55% 5 years after transplantation. There was a higher rate of complications related to the procedure in the PTx group. Severe hypoglycemia was eliminated in the majority of both ITx and PTx recipients. CONCLUSION: This report proves the successful initiation of pancreatic islet transplantation in a center with a well-established PTx program. ITx has been shown to be the method of choice for hypoglycemia unawareness syndrome, and may be considered for application in clinical practice if conservative options are exhausted.

Fulltext: HTML , PDF (484KB)